Phase 2 Rheumatoid Arthritis Trial, Recruiting NCT07062523 Sponsor: Peking Union Medical College Hospital Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 2 Rheumatoid Arthritis Trial, Recruiting

NCT07062523
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People who have been diagnosed with primary Sjögren's syndrome (a condition that affects the immune system, often causing dry eyes and dry mouth) according to recognised 2016 classification guidelines, OR people who have been diagnosed with a solid tumour (a type of cancer) and are already scheduled for a specific type of scan called a FAPI PET scan

Who may not be able to join:

  • People in the Sjögren's syndrome group who also have cancer or another connective tissue disease (a group of conditions affecting the body's structural tissues)
  • People in either group who are currently taking hormone treatments or biological medicines (a type of medication made from living cells)
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhaohui Zhu, MD, Peking Union Medical College Hospital

Phone: 13611093752

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
1 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Optimal imaging time; Correlation with inflammatory markers; Comparative uptake analysis between Sjögren's syndrome and tumor patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov